Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 5, 2008, Pages 545-555

  Andresen, Viola ^a,c   Montori, Victor M ^b   Keller, Jutta ^c   West, Colin P ^b   Layer, Peter ^c   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CILANSETRON; MEBEVERINE; PLACEBO; SEROTONIN; SEROTONIN 3 ANTAGONIST;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROL GROUP; DRUG EFFECT; EMBASE; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; MEDLINE; META ANALYSIS; METHODOLOGY; POPULATION; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; CARBAZOLES; CARBOLINES; CONSTIPATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PHENETHYLAMINES; PROGNOSIS; PYRIDINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42749097353     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.12.015     Document Type: Article

References (47)

1. Drossman D.A., Sandler R.S., McKee D.C., et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 83 (1982) 529-534
2. Talley N.J., Zinsmeister A.R., Van Dyke C., et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101 (1991) 927-934
3. Jones R., and Lydeard S. Irritable bowel syndrome in the general population. BMJ 304 (1992) 87-90
4. Drossman D.A., Li Z., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38 (1993) 1569-1580
5. Thompson W.G., Longstreth G.F., Drossman D.A., et al. Functional bowel disorders and functional abdominal pain. Gut 45 Suppl 2 (1999) II43-II47
6. Foxx-Orenstein A.E., Kuemmerle J.F., and Grider J.R. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 111 (1996) 1281-1290
7. Kim D.Y., and Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95 (2000) 2698-2709
8. Moss H.E., and Sanger G.J. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 100 (1990) 497-501
9. Banner S.E., and Sanger G.J. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 114 (1995) 558-562
10. Miura M., Lawson D.C., Clary E.M., et al. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 44 (1999) 20-24
11. Kozlowski C.M., Green A., Grundy D., et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 46 (2000) 474-480
12. Delvaux M., Louvel D., Mamet J.P., et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 12 (1998) 849-855
13. Kuo B., Camilleri M., Burton D., et al. Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 16 (2002) 225-233
14. Houghton L.A., Foster J.M., and Whorwell P.J. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14 (2000) 775-782
15. Stacher G., Weber U., Stacher-Janotta G., et al. Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. Br J Clin Pharmacol 49 (2000) 429-436
16. Camilleri M. Pharmacology and clinical experience with alosetron. Expert Opin Investig Drugs 9 (2000) 147-159
17. Lembo T., Wright R.A., Bagby B., et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96 (2001) 2662-2670
18. Watson M.E., Lacey L., Kong S., et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96 (2001) 455-459
19. Camilleri M., Mayer E.A., Drossman D.A., et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13 (1999) 1149-1159
20. Jones R.H., Holtmann G., Rodrigo L., et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 13 (1999) 1419-1427
21. Miner P., Stanton D.B., Carter F., et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 3-month US study. Am J Gastroenterol 99 (2004) S 277(abstract)
22. Bradette M., Moennikes H., Carter F., et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 months global study. Gastroenterology 126 (2004) A-42
23. Veldhuyzen van Zanten S.J., Talley N.J., Bytzer P., et al. Design of treatment trials for functional gastrointestinal disorders. Gut 45 Suppl 2 (1999) II69-II77
24. Camilleri M., Mangel A.W., Fehnel S.E., et al. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 5 (2007) 534-540
25. Olden K., DeGarmo R.G., Jhingran P., et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 97 (2002) 3139-3146
26. Viramontes B.E., Camilleri M., McKinzie S., et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96 (2001) 2671-2676
27. Cremonini F., Delgado-Aros S., and Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 15 (2003) 79-86
28. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354 (1999) 1896-1900
29. Camilleri M., Northcutt A.R., Kong S., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355 (2000) 1035-1040
30. Camilleri M., Chey W.Y., Mayer E.A., et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 161 (2001) 1733-1740
31. Bardhan K.D., Bodemar G., Geldof H., et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 14 (2000) 23-34
32. Lembo A.J., Olden K.W., Ameen V.Z., et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2 (2004) 675-682
33. Juni P., Altman D.G., and Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323 (2001) 42-46
34. Chey W.D., Chey W.Y., Heath A.T., et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 99 (2004) 2195-2203
35. Krause R., Ameen V., Gordon S., et al. Safety and efficacy of 0.5 mg qd, 1 mg qd, and 1 mg bid alosetron hydrochloride in women with chronic, severe diarrhea-predominant IBS (IBS-D). Gastroenterology 130 (2006) A-320
36. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
37. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. BMJ 326 (2003) 219
38. Chang L., Ameen V.Z., Dukes G.E., et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100 (2005) 115-123
39. Wolfe S.G., Chey W.Y., Washington M.K., et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol 96 (2001) 803-811
40. Francisconi C.F., Drossman D., Mayer E.A., et al. Relief of symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) patients decreases after blinded withdrawal of cilansetron treatment. Gastroenterology 128 (2005) A 465(abstract)
41. Lau J., Ioannidis J.P., Terrin N., et al. The case of the misleading funnel plot. BMJ 333 (2006) 597-600
42. Furukawa T.A., Watanabe N., Omori I.M., et al. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 297 (2007) 468-470
43. Mayer E.A., Berman S., Derbyshire S.W., et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 16 (2002) 1357-1366
44. Delvaux M., Louvel D., Mamet J.P., et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 12 (1998) 849-855
45. Efskind P.S., Bernklev T., and Vatn M.H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 31 (1996) 463-468
46. Chang L., Chey W.D., Harris L., et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101 (2006) 1069-1079
47. Camilleri M. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT(3) antagonist treatment?. Neurogastroenterol Motil 19 (2007) 77-84